Why is tirzepatide an injection and not a tablet?
Tirzepatide is a dual GLP-1/GIP receptor agonist peptide used for weight management support. Like most therapeutic peptides, it faces a fundamental pharmacological challenge with oral administration: peptides are broken down by enzymes in the digestive tract and do not cross the intestinal wall into the bloodstream efficiently without specialized formulation.
When you swallow a peptide in tablet form, stomach acid and proteolytic enzymes begin breaking it into amino acids before it reaches the small intestine. Even what survives that process faces another barrier: the intestinal epithelium is not designed to transport large peptide molecules. The result is low and variable bioavailability — a much smaller fraction of the dose reaching systemic circulation compared to injection.
Subcutaneous injection bypasses the digestive barrier entirely. The peptide is deposited into fat tissue just under the skin, where it is absorbed directly into the bloodstream. This route delivers predictable, consistent bioavailability, which is why it is the standard for GLP-1 protocols.
The subcutaneous injection in practice
Compounded tirzepatide is formulated for subcutaneous injection, typically administered once weekly. The practical reality is less daunting than it sounds to most people approaching it for the first time.
Injection site and technique
Subcutaneous injections are given into the fatty layer under the skin on the abdomen, thigh, or upper arm. The needles used are fine-gauge, typically 31–32G, and short. Most people report the sensation as a brief, minor pinch. Injection sites are rotated to avoid repeated injection into the same spot.
Clinician programs provide injection technique guidance as part of the onboarding process. The learning curve is short — most people find the process routine within the first few administrations.
Once-weekly dosing
Tirzepatide has a long half-life that supports once-weekly dosing. This is a meaningful practical advantage: weekly injection is significantly less burdensome than daily or twice-daily administration. Most people pick a consistent day of the week and stay with it.
The reason tirzepatide is injected, not swallowed, is biology — digestive enzymes destroy the peptide before it can work.
Is there an oral tirzepatide tablet in development?
Oral GLP-1 formulations are an active area of pharmaceutical development. The scientific challenge is enabling enough absorption of the peptide through the GI tract to achieve therapeutic systemic concentrations. Several approaches are being explored, including absorption enhancers and modified peptide structures designed to resist GI breakdown.
Oral semaglutide (a related GLP-1 peptide) has reached the market in branded form through a specific absorption-enhancement technology, providing a proof-of-concept that oral GLP-1 delivery is achievable. Its bioavailability is roughly 1% compared to injection, which means oral doses are considerably higher than injectable doses to achieve equivalent plasma levels.
Oral tirzepatide formulations have been in development, but as of current writing they are not available through licensed U.S. 503A compounding pharmacies. Compounded tirzepatide is formulated for subcutaneous injection. Anyone offering a compounded oral tirzepatide tablet through a telehealth platform should be able to identify the licensed 503A pharmacy and the specific formulation — the absence of that transparency is a meaningful concern.
Oral tablet vs subcutaneous injection: how do they compare?
People comparing tirzepatide options often also compare tirzepatide to semaglutide, or ask how oral and injectable GLP-1 delivery differ across every dimension that matters.
| Factor | Oral tablet | Subcutaneous injection |
|---|---|---|
| Availability (tirzepatide) | Not available (in development) | Available — branded & compounded 503A |
| Bioavailability | Very low for peptides; requires specialized formulation | High and consistent; bypasses GI tract |
| Dosing frequency | Daily (oral semaglutide); tirzepatide TBD | Once weekly |
| Dosing variability | Affected by meal timing, gastric pH, GI transit | Predictable; independent of meals |
| Patient experience | No needle; pill-taking familiarity | Fine-gauge needle; most find it routine quickly |
| Clinician oversight | Required for both routes | Required for both routes |
The key pharmacological distinction between tirzepatide and semaglutide specifically is the receptor profile.
Semaglutide targets the GLP-1 receptor only. Tirzepatide targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which is why it is described as a dual agonist. GIP is another incretin hormone involved in insulin secretion and fat metabolism. The dual-target mechanism accounts for the research interest in comparing outcomes between the two peptides.
Both are available as compounded injectables through licensed U.S. 503A pharmacies. Neither branded nor compounded versions should be described as FDA-approved for compounded formulations. A licensed clinician can help determine which peptide is more appropriate based on your health profile and goals.
Explore PepScribe’s tirzepatide program or semaglutide program to see what each protocol includes.
What the titration schedule looks like
Whether using injectable tirzepatide or semaglutide, dose titration is central to the protocol. GI side effects — nausea, delayed gastric emptying — are most common at the start of treatment and during dose increases. A structured titration that increases dose gradually over several weeks gives the body time to adapt, which significantly reduces the likelihood of discontinuing due to tolerability.
The titration schedule is managed by the prescribing clinician, not by the patient independently. This is one of the reasons that a program with ongoing monitoring check-ins is meaningfully different from a service that issues a prescription and provides no follow-up.
Frequently asked questions
Is there a tirzepatide tablet form available?
Branded oral tirzepatide has been in development, and an oral formulation exists in research settings. However, as of current writing, compounded tirzepatide available through licensed U.S. 503A pharmacies is formulated for subcutaneous injection, not as an oral tablet.
Why is tirzepatide typically given as an injection rather than a tablet?
Tirzepatide is a peptide, and peptides are generally broken down in the digestive tract before they can be absorbed into the bloodstream. The subcutaneous injection route bypasses this degradation, allowing reliable delivery of the active peptide. Oral peptide delivery requires specialized formulation to improve bioavailability.
How does subcutaneous tirzepatide injection work?
A small-gauge needle delivers tirzepatide into the subcutaneous fat layer, typically on the abdomen, thigh, or upper arm. From there it is absorbed into the bloodstream. Injections are typically once weekly with compounded tirzepatide protocols.
Is injectable tirzepatide painful?
Most patients find subcutaneous injection with the fine-gauge needles used in GLP-1 protocols to be minimal discomfort. The technique is simple and quickly routine for most people. Proper technique is reviewed as part of a licensed clinician program.
What is the difference between tirzepatide and semaglutide for injection?
Both are injectable GLP-1 receptor agonist peptides used in weight management. Tirzepatide is a dual GLP-1/GIP agonist, targeting two receptors compared to semaglutide's single GLP-1 receptor. Clinical trials have compared outcomes between the two; a clinician can help determine which is more appropriate based on your individual health profile.
Can I switch from an injection to an oral form of tirzepatide?
Oral tirzepatide formulations are in development but not currently available through licensed U.S. 503A compounding channels. Any switch in formulation or route of administration should be guided by a licensed clinician who can account for bioavailability differences and dose adjustment.